Etiometry adds more clinical decision support tools to its platform with 510(k) clearance

The platform offers end-to-end data management software solutions for the collection, analysis, visualization and archiving of ICU clinical data.
By Mallory Hackett
11:41 am
Share
The platform offers end-to-end data management software solutions for the collection, analysis, visualization and archiving of ICU clinical data.

Etiometry has received 510(k) clearance from the U.S. Food and Drug Administration to add enhancements to its clinical decision support platform for the intensive care environment.

Its platform offers end-to-end data management software solutions for the collection, analysis, visualization and archiving of ICU clinical data.

With its T3 Data Aggregation and Visualization software, clinicians get a look at real-time patient health data combined in one dashboard. From there, the platform uses its Risk Analytics Engine to indicate the likelihood a patient will experience a harmful physiologic state.

Learn on-demand, earn credit, find products and solutions. Get Started >>

Because the software stores the clinical data, it can be viewed retroactively for research, quality improvement initiatives and reporting.

WHY THIS MATTERS

The regulatory clearance provides three main updates to the Etiometry platform’s patient risk indices.

The first provides flexibility to adjust index thresholds to view individualized patient risk assessments based on their condition and needs. Clinicians can now set patient-specific thresholds for the risk of inadequate delivery of oxygen (IDO2 Index) or ventilation of carbon dioxide (IVOC2 Index).

The second gives clinicians insights into what health metrics are contributing to changes in their patients’ risk scores. To see the contributing factors, clinicians hover over a trended risk index within the platform.

The third is the addition of Etiometry’s Surveillance View, which provides remote, system-wide viewing of patients’ data on a single display.

THE LARGER TREND

This marks Etiometry’s sixth FDA clearance for its platform. Last year, it added the IVOC2 Index, which joined the previously cleared IDO2 Index.

Tech-enabled clinical decision support tools are becoming an increasingly hot commodity. The space has seen notable fundings from Ultromics for its cardiac decision support tool and KēlaHealth for its intelligent surgical-risk-prediction platform.

There’s also been recent activity in M&As for this area, including the acquisition of Apixio by Centene. Apixio's platform finds and compiles patient data from physician notes, medical charts and other clinical documents.

Clinical decision support has even crept into the pharmacy with Tabula Rasa HealthCare launching MedWise, a platform for pharmacists to cumulatively compare how different medications interact with each other.

ON THE RECORD

“With the new flexibility to accommodate different patient conditions and the increased transparency of our indices, we have a stepping stone into new markets and effective drivers for further clinical utilization that broaden the benefits of the Etiometry Platform,” said Dimitar Baronov, the chief technology officer and cofounder of Etiometry, in a statement.

 

MobiHealthNews:

The latest news in digital health delivered daily to your inbox.

Thank you for subscribing!
Error! Something went wrong!